Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

manilatimes.net · 2026-08-31

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation.

TickrTrends take: Axsome Therapeutics is advancing AXS-05 into late-stage clinical testing for smoking cessation, a condition affecting millions of smokers globally and representing a substantial market opportunity if regulatory approval is achieved. The Phase 3 SUMMIT trial outcome will be a critical data point for determining the commercial viability of this indication, directly influencing the company's valuation once results become available. Investors focused on valuation should monitor trial enrollment rates and interim data readouts, as clinical success or failure in this program could materially impact Axsome's revenue projections and pipeline value.

Read the full story at manilatimes.net →